Optimized immunohistochemical panel to differentiate myeloid sarcoma from blastic plasmacytoid dendritic cell neoplasm

Modern Pathology

Volumn 27, Issue 8, 2014, Pages 1137-1143

  Sangle, Nikhil A ^a   Schmidt, Robert L ^a   Patel, Jay L ^b   Jeffrey Medeiros, L ^c   Agarwal, Archana M ^a   Perkins, Sherrie L ^a   Salama, Mohamed E ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALGARY   (Canada)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Myeloid sarcoma BPDCN immunohistochemical panel

Indexed keywords

BLOOD DENDRITIC CELL ANTIGEN 2; CD123 ANTIGEN; CD14 ANTIGEN; CD163 ANTIGEN; CD33 ANTIGEN; CD4 ANTIGEN; CD56 ANTIGEN; CELL ANTIGEN; CHLORDANE; CUTANEOUS LYMPHOCYTE ASSOCIATED ANTIGEN; DNA NUCLEOTIDYLEXOTRANSFERASE; LYSOZYME; MYELOPEROXIDASE; MYXOVIRUS RESISTANCE PROTEIN A; UNCLASSIFIED DRUG; TUMOR MARKER; ANTIBODY; CD68 ANTIGEN; CELL MARKER; FORMALDEHYDE; LEUKOSIALIN; MEMBRANE PROTEIN; MYXOVIRUS A PROTEIN; P SELECTIN GLYCOPROTEIN LIGAND 1; PARAFFIN; T CELL LEUKEMIA 1 PROTEIN;

ADOLESCENT; ADULT; AGED; ARTICLE; BLASTIC NK CELL LYMPHOMA; BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM; CHILD; CLINICAL ARTICLE; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; FEMALE; GRANULOCYTIC SARCOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFANT; MALE; NEWBORN; PLASMACYTOID DENDRITIC CELL; PREDICTIVE VALUE; PRIORITY JOURNAL; STAINING; TUMOR CLASSIFICATION; TUMOR DIFFERENTIATION; CHEMISTRY; COMPARATIVE STUDY; DENDRITIC CELL; HEMATOLOGIC DISEASE; IMMUNOPHENOTYPING; METABOLISM; MIDDLE AGED; PATHOLOGY; PRESCHOOL CHILD; SKIN TUMOR; VERY ELDERLY; YOUNG ADULT; CLASSIFICATION; COHORT ANALYSIS; MYELOPROLIFERATIVE DISORDER; SCHOOL CHILD; TISSUE DIFFERENTIATION; TISSUE SECTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; DENDRITIC CELLS; DIAGNOSIS, DIFFERENTIAL; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; INFANT; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; SARCOMA, MYELOID; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84905438690     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2013.238     Document Type: Article

References (24)

1. Adachi M, Maeda K, Takekawa M, et al. High expression of CD56 (N-CAM) in a patient with cutaneous CD4-positive lymphoma. Am J Hematol 1994;47:278-282.
2. Chaperot L, Bendriss N, Manches O, et al. Identification of a leukemic counterpart of the plasmacytoid dendritic cells. Blood 2001;97:3210-3217.
3. Petrella T, Comeau MR, Maynadie M, et al. 'Agranular CD4+ CD56+ hematodermic neoplasm' (blastic NK-cell lymphoma) originates from a population of CD56+ precursor cells related to plasmacytoid monocytes. Am J Surg Pathol 2002;26:852-862.
4. Stein H, Warnke RA, Chan WC. Diffuse large B-cell lymphoma, not otherwise specified, In: Swerdlow SH, Campo E, Harris NL et al. (eds). WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues. 4th edn. IARC Press: Lyon, France; 2008, pp 233-239.
5. Urosevic M, Conrad C, Kamarashev J, et al. CD4+ CD56+ hematodermic neoplasms bear a plasmacytoid dendritic cell phenotype. Hum Pathol 2005;36: 1020-1024.
6. Petrella T, Bagot M, Willemze R, et al. Blastic NK-cell lymphomas (agranular CD4+CD56+ hematodermic neoplasms): a review. Am J Clin Pathol 2005;123: 662-675.
7. Petrella T, Meijer CJ, Dalac S, et al. TCL1 and CLA expression in agranular CD4/CD56 hematodermic neoplasms (blastic NK-cell lymphomas) and leukemia cutis. Am J Clin Pathol 2004;122:307-313.
8. Menasce LP, Banerjee SS, Beckett E, et al. Extramedullary myeloid tumour (granulocytic sarcoma) is often misdiagnosed: a study of 26 cases. Histopathology 1999;34:391-398.
9. Benet C, Gomez A, Aguilar C, et al. Histologic and immunohistologic characterization of skin localization of myeloid disorders: a study of 173 cases. Am J Clin Pathol 2011;135:278-290.
10. Roth MJ, Medeiros LJ, Elenitoba-Johnson K, et al. Extramedullary myeloid cell tumors. An immunohistochemical study of 29 cases using routinely fixed and processed paraffin-embedded tissue sections. Arch of Pathol Lab Med 1995;119:790-798.
11. Ratnam KV, Su WP, Ziesmer SC, et al. Value of immunohistochemistry in the diagnosis of leukemia cutis: study of 54 cases using paraffin-section markers. J Cutan Pathol 1992;19:193-200.
12. Kaddu S, Zenahlik P, Beham-Schmid C, et al. Specific cutaneous infiltrates in patients with myelogenous leukemia: a clinicopathologic study of 26 patients with assessment of diagnostic criteria. J Am Acad Dermatol 1999;40:966-978.
13. Tsagarakis NJ, Kentrou NA, Papadimitriou KA, et al. Acute lymphoplasmacytoid dendritic cell (DC2) leukemia: results from the Hellenic Dendritic Cell Leukemia Study Group. Leukemia Res 2010;34:438-446.
14. Dalle S, Beylot-Barry M, Bagot M, et al. Blastic plasmacytoid dendritic cell neoplasm: is transplantation the treatment of choice? Br J Dermatol 2010;162:74-79.
15. Dietrich S, Andrulis M, Hegenbart U, et al. Blastic plasmacytoid dendritic cell neoplasia (BPDC) in elderly patients: results of a treatment algorithm employing allogeneic stem cell transplantation with moderately reduced conditioning intensity. Biol Blood Marrow Transplant 2011;17:1250-1254.
16. Cibull TL, Thomas AB, O'Malley DP, et al. Myeloid leukemia cutis: a histologic and immunohistochemical review. J Cutan Pathol 2008;35:180-185.
17. Ascani S, Massone C, Ferrara G, et al. CD4-negative variant of CD4+/CD56+ hematodermic neoplasm: description of three cases. J Cutan Pathol 2008;35:911-915.
18. Argyrakos T, Rontogianni D, Karmiris T, et al. Blastic natural killer (NK)-cell lymphoma: report of an unusual CD4 negative case and review of the CD4 negative neoplasms with blastic features in the literature. Leukemia Lymphoma 2004;45:2127-2133.
19. Cota C, Vale E, Viana I, et al. Cutaneous manifestations of blastic plasmacytoid dendritic cell neoplasm-morphologic and phenotypic variability in a series of 33 patients. Am J Surg Pathol 2010;34:75-87.
20. Herling M, Teitell MA, Shen RR, et al. TCL1 expression in plasmacytoid dendritic cells (DC2s) and the related CD4+ CD56+ blastic tumors of skin. Blood 2003;101:5007-5009.
21. Cronin DM, George TI, Reichard KK, et al. Immunophenotypic analysis of myeloperoxidase-negative leukemia cutis and blastic plasmacytoid dendritic cell neoplasm. Am J Clin Pathol 2012;137:367-376.
22. Tsuchiyama J, Yoshino T, Toba K, et al. Induction and characterization of cutaneous lymphocyte antigen on natural killer cells. Br J Haematol 2002;118:654-662.
23. Jaye DL, Geigerman CM, Herling M, et al. Expression of the plasmacytoid dendritic cell marker BDCA-2 supports a spectrum of maturation among CD4+ CD56+ hematodermic neoplasms. Mod Pathol 2006;19:1555-1562.
24. Pilichowska ME, Fleming MD, Pinkus JL, et al. CD4+/ CD56+ hematodermic neoplasm ("blastic natural killer cell lymphoma"): neoplastic cells express the immature dendritic cell marker BDCA-2 and produce interferon. Am J Clin Pathol 2007;128:445-453.